Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

ully in line with the results of the earlier Japanese studies," said Andrew R. Allen, executive vice president and chief medical officer of Pharmion Corporation. "We are pleased to see these exciting data reproduced in patients in the western hemisphere, as we expected, and we look forward to this pivotal trial and further investigating amrubicin's potential as a major advance for patients with small cell lung cancer."

About Amrubicin

Pharmion licensed the rights to amrubicin in November 2006. In 2002, amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 62,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... BENICIA, Calif., Jan. 22 AcroMetrix, a global ... diagnostics,announced today that it will extend its contract ... December 31st of 2009. Following,the previous agreement from ... as a recommended provider of quality control materials,for ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), today announced ... an animal study conducted as part of its,Acetylcholinesterase ... under the agreement the Company entered into,with the ... of the Hebrew University of Jerusalem, Israel, and ...
Cached Medicine Technology:AcroMetrix Renews Contract With Group Services for America's Blood Centers 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce ... Services at North Carolina State’s College of Veterinary Medicine ... Award for Distinguished Volunteer Service—the organization’s highest award. ... of volunteer experts to direct its work to improve ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... NEW YORK, June 24 According to the ... from diabetes,asthma and other chronic conditions. The medical care ... the nation,s $2 trillion medical care,costs. And as the ... its medical bills are expected to spiral further out ...
... a latency period of 10-50,years, and with millions of ... of this life ending disease continue,to disrupt families and ... leadership, members of Congress and three guest speakers,who will ... The press conference will be held on the ...
... to Reduce ... Impact of Diagnosed Health Conditions, LAGUNA HILLS, Calif., ... tasty, satisfying foods that help people prevent and,manage Diabetes ... snack bars in over 200 Southern California Ralph,s,grocery stores. ...
... 2008) The American Academy of Cosmetic Surgery has released ... opinions on medical spas. Findings revealed that millennials, those ... these facilities. Yet half of those women are compromising ... , Women ages 18-34 were more than three times as ...
... Brompton and Harefield NHS Trust,s Leadership Role in the Treatment ... ... Stereotaxis, Inc. (Nasdaq:,STXS) announced that British Prime Minister Gordon Brown presided ... lab at,Royal Brompton Hospital in London. The new lab features Stereotaxis ...
... (NYSE:,HRC) today announced the signing of a distribution ... agreement will enhance selling,efforts for Hill-Rom,s product The ... care facilities within the United States., "We ... said Kim,Dennis, group vice president, Post Acute Care ...
Cached Medicine News:Health News:Healthcare Experts Discuss Current and Future Challenges of Chronic Care on NewTalk 2Health News:Healthcare Experts Discuss Current and Future Challenges of Chronic Care on NewTalk 3Health News:Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients 2Health News:Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition(TM) 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: